Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers.
On September 7, 2022, Gavin Isaacs notified Altitude Acquisition Corp. (the
"Company") of his decision to resign from his position as Chairman of the board
of directors of the Company (the "Board") and from the audit committee of the
Board (the "Audit Committee"), effective immediately. Mr. Isaacs' decision to
resign was due to increasing responsibilities in his other executive roles and
was not related to any disagreement with the Company on any matter relating to
the Company's operations, policies or practices.
On September 9, 2022, Thomas Breitling notified the Company of his decision to
resign from his position as Vice Chairman of the Board and from the compensation
committee of the Board (the "Compensation Committee"), effective immediately.
Mr. Breitling's decision to resign was due to increasing responsibilities in his
other executive roles and was not related to any disagreement with the Company
on any matter relating to the Company's operations, policies or practices.
In connection with the resignations of Mr. Isaacs and Mr. Breitling, the Board
determined to reduce the size of the board to five members.
In connection with the resignations of Mr. Isaacs and Mr. Breitling, on
September 13, 2022, the Board appointed Dr. Warren Hosseinion to serve as a
Class III director on the Board, Chairman of the Board, and as a member of the
Audit Committee and Compensation Committee, effective immediately.
Dr. Hosseinion, 46, is a co-founder of Apollo Medical Holdings, Inc., has been a
member of its board of directors since July 2008, and served as its Chief
Executive Officer from July 2008 to December 2017 and Co-Chief Executive Officer
from December 2017 to March 2019. Dr. Hosseinion was Chairman of the board of
directors of Clinigence Holdings, Inc. from April 2019 to March 2022, Chief
Executive Officer of Clinigence Holdings, Inc. from March 2021 to March 2022,
and following a business combination with Nutex Health, Inc. he continues to be
a director and President of Nutex Health, Inc. from March 2022 to present. In
2001, Dr. Hosseinion co-founded ApolloMed. Dr. Hosseinion received his B.S. in
Biology from the University of San Francisco, his M.S. in physiology and
biophysics from the Georgetown University Graduate School of Arts and Sciences,
his medical degree from the Georgetown University School of Medicine, and
completed his residency in internal medicine from the Los Angeles
County-University of Southern California Medical Center.
There are no arrangements or understandings between Dr. Hosseinion and any other
persons pursuant to which Dr. Hosseinion was selected as a member of the Board,
there are no family relationships between Dr. Hosseinion and any director or
executive officer of the Company, and there are no related party transactions
between the Company and Dr. Hosseinion that would require disclosure under
Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as
amended.
In connection with the appointment of Dr. Hosseinion to the Board, the Company
entered into an indemnification agreement and a letter agreement with
Dr. Hosseinion, on substantially the same terms as the forms of indemnification
agreement and letter agreement previously entered into by and between the
Company and each of its other officers and directors in connection with the
Company's initial public offering. The forms of the Company's standard
indemnification agreement and letter agreement are included as Exhibits 10.1 and
10.5, respectively, to the Company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2021, filed by the Company with the Securities and
Exchange Commission on March 29, 2022.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ALTITUDE ACQUISITION CORP. 
